Microcap Ledger Registered direct offerings: how big is the discount, and what happens to the stock? What 832 deals show
We tracked 832 registered direct offerings by Nasdaq and NYSE American microcaps from 2021 to 2026. The typical deal priced 4.6% below the prior close. Sixty trading days later, the typical stock was down 36%.
- Study period
- January 2021 to October 2026 (prices to the Oct 12, 2026 close)
- Sample
- 832 offerings by 440 companies
The short version
- The headline discount was small: the median offering priced 4.6% below the prior close, and 31% priced above it. Deals with warrants attached had a median discount of just 1.1%, against 13.6% for deals without.
- The stock usually fell anyway. The median return from the prior close was −6.6% after one session, −23% after 20, −36% after 60 and −52% after 120. 81% of stocks were lower after 60 sessions. Small caps as a whole (IWM) rose a median 2% over the same 60 sessions.
- 86% of stocks closed below the offering price at least once within 20 sessions. With warrants attached, 94% did.
- 108 offerings came after the stock had risen 50% or more in the five sessions before. Those priced a median 25% below the prior close, and the stock was down a median 56% after 60 sessions.
- Larger deals relative to the company went with larger declines: −30% at 60 days for raises under 10% of market cap, −43% for raises of half the market cap or more. These companies chose to raise, so the study shows what followed, not what caused it.
Registered direct offerings by microcaps usually price close to the market, then the stock falls well below that price. We tracked 832 of them by Nasdaq and NYSE American companies worth under $300 million, from January 2021 to October 2026. The median deal priced 4.6% below the prior close. The median stock was down 6.6% after one session, 23% after 20 trading days, 36% after 60 and 52% after 120.
That’s a record of what followed, not a forecast or proof of cause. Companies choose when to raise, and most of these were small, cash-hungry businesses: the median market cap was $30 million and the median raise $5 million, about 18% of the company’s value.
How a registered direct works
A company with an effective shelf registration sells shares straight to a few investors at a fixed price, usually through a placement agent, and the deal is often agreed overnight and announced before the open. Our registered direct explainer covers the mechanics, and ELOC vs ATM vs registered direct compares it with the other common tools.
How big is the discount?
Offering price vs the prior close
Chart data
| Range | Events |
|---|---|
| −80.0% to −70.0% | 0 |
| −70.0% to −60.0% | 7 |
| −60.0% to −50.0% | 8 |
| −50.0% to −40.0% | 23 |
| −40.0% to −30.0% | 39 |
| −30.0% to −20.0% | 97 |
| −20.0% to −10.0% | 163 |
| −10.0% to 0.0% | 159 |
| 0.0% to +10.0% | 239 |
| +10.0% to +20.0% | 44 |
| +20.0% to +30.0% | 22 |
| +30.0% to +40.0% | 31 |
60% of deals priced below the prior close, 9% exactly at it and 31% above it. The 10th percentile was a 29% discount; the 90th, a 12% premium. The mean was −6.5%.
Two features explain the small headline number. First, 40% of deals were described as “priced at-the-market under Nasdaq rules”. Nasdaq’s Minimum Price is the lower of the last close and the five-day average close, and a deal at or above it doesn’t need a shareholder vote. Those deals had a median discount of 0.6%.
Second, warrants. 60% of deals gave investors ordinary warrants, typically one for each share, with a median exercise price equal to the offering price. 40% of all deals sold those warrants in a concurrent private placement. The warrant is part of what investors pay for, so the share price alone understates the cost.
Discount and returns, with and without warrants
Chart data
| Median discount | Median +20 days | Median +60 days | Events | |
|---|---|---|---|---|
| With warrants | −1.1% | −25.3% | −40.6% | 502 |
| No warrants | −13.6% | −16.7% | −29.1% | 330 |
Deals with warrants priced at a median 1.1% discount; deals without them, 13.6%. The deals with warrants then did worse: −41% at 60 sessions against −29%.
What happened to the stock
Median return after a registered direct offering
Chart data
| Median return | Median vs IWM | Events | |
|---|---|---|---|
| +1 | −6.6% | −6.4% | 832 |
| +5 | −12.0% | −12.2% | 830 |
| +20 | −22.6% | −23.0% | 818 |
| +60 | −35.7% | −37.5% | 798 |
| +120 | −51.8% | −52.6% | 755 |
69% of stocks fell on the first day. By day +60, 81% were lower. Means were less severe than medians (−27% at day +60) because a few stocks rose several-fold. At day +60 the 10th percentile was −74% and the 90th was +25%.
The offering price didn’t act as a floor. 86% of stocks closed below it at least once within 20 sessions, and 51% did so on the first day. With warrants attached the figure was 94%; without, 73%. Our dilution guide explains how new shares change each holder’s stake.
Selling into a spike
Some companies raised right after a sharp rise. 108 offerings (13%) came after the stock had gained 50% or more in the five sessions before the prior close.
Offerings that followed a 50% run-up
Chart data
| Median discount | Median +20 days | Median +60 days | Events | |
|---|---|---|---|---|
| Up 50%+ in prior 5 sessions | −25.0% | −46.1% | −55.8% | 108 |
| Up under 50% or down | −1.7% | −19.8% | −33.0% | 724 |
Those deals priced at a median 25% discount to the prior close, against 1.7% for the rest. That’s partly the Nasdaq rule at work: after a run-up, the five-day average sits well below the last close, so an “at-the-market” price can still be far below it. Of the 101 at-market deals that priced more than 10% below the prior close, 83 were at, above or within 3% of the five-day average close. The stocks then fell a median 21% on day one and 56% by day +60; 93% were lower after 60 sessions.
This is a known pattern. The data shows the sequence; it doesn’t show the raise caused the fall, since some of the run-ups would likely have faded anyway.
Size, agent and year
Bigger raises relative to the company went with bigger declines.
Discount and 60-day return by deal size relative to market cap
Chart data
| Median discount | Median +60 days | Events | |
|---|---|---|---|
| Under 10% | −11.4% | −29.9% | 198 |
| 10% to 25% | −8.8% | −35.8% | 335 |
| 25% to 50% | 0.0% | −38.8% | 180 |
| 50% or more | +0.5% | −43.0% | 119 |
Raises under 10% of market cap had a median 60-day return of −30%; raises of half the market cap or more, −43%. The smaller raises carried the bigger discounts: −11% for raises under 10% of market cap, about zero for raises of a quarter or more.
Discount and 60-day return by placement agent
Chart data
| Median discount | Median +60 days | Events | |
|---|---|---|---|
| H.C. Wainwright | −1.9% | −39.3% | 194 |
| A.G.P. | −6.0% | −34.2% | 99 |
| Maxim Group | −4.9% | −43.3% | 63 |
| Roth Capital | −13.3% | −48.3% | 48 |
| Aegis Capital | −9.7% | −54.8% | 17 |
| All other agents | −7.6% | −40.1% | 211 |
| No agent named | −1.6% | −18.3% | 200 |
H.C. Wainwright placed 194 deals, A.G.P. 99, Maxim 63, Roth 48 and Aegis 17. Their median 60-day returns ran from −34% (A.G.P.) to −55% (Aegis). The 200 deals with no placement agent named did best, at −18%. The groups differ in company type and size, so this isn’t a ranking of agents.
| Year | Offerings | Median discount | Median +60 days |
|---|---|---|---|
| 2021 | 122 | −8.6% | −33.0% |
| 2022 | 86 | 0.0% | −38.0% |
| 2023 | 157 | −3.2% | −44.9% |
| 2024 | 197 | −3.8% | −34.9% |
| 2025 | 173 | −9.5% | −31.1% |
| 2026 | 97 | −5.7% | −36.7% (71 with 60 days of data) |
Every year had a median 60-day decline of 31% or more.
The outliers
Returns from the prior close to day +60. Context is what the company filed in the window, not a claim about why the stock moved.
| Company | Priced | Agent, size | Mkt cap | Discount | +60 days | Filed in the window |
|---|---|---|---|---|---|---|
| GeoVax Labs (GOVX) | May 22, 2024 | Roth, $1.3M | $3.7M | +4.3% | +339% | BARDA award for a Phase 2b COVID-19 vaccine trial, Jun 2024 |
| Veritone (VERI) | Jun 30, 2025 | D. Boral, $10.0M | $64.3M | −23.2% | +316% | $25M underwritten offering at $2.63, Sep 2025 |
| Palladyne AI (PDYN) | Oct 31, 2024 | A.G.P., $7.0M | $59.8M | −3.6% | +292% | At-the-market sales agreement with Jefferies, Nov 2024 |
| Bellerophon Therapeutics (BLPH) | Mar 6, 2023 | None named, $5.0M | $17.3M | +10.6% | +290% | Last patient completed blinded treatment in its Phase 3 study, May 2023 |
| INNO Holdings (INHD) | Jun 3, 2025 | None named, $0.5M | $6.6M | −66.7% | +259% | Standby equity purchase agreement, Jul 2025 |
| SUNation Energy (SUNE) | Feb 27, 2025 | Roth, $20.0M | $2.1M | 0.0% | −99% | Authorized shares raised to 1 billion, Apr 2025 |
| Aclarion (ACON) | Jan 3, 2025 | Dawson James, $0.5M | $1.5M | 0.0% | −99% | Underwritten unit offering, about $14.6M, Jan 2025 |
| Aditxt (ADTX) | Aug 9, 2024 | H.C. Wainwright, $1.2M | $2.1M | −15.2% | −99% | Reverse stock split, Oct 2024 |
| Greenwave Technology (GWAV) | May 17, 2024 | Dawson James, $21.9M | $6.5M | −64.9% | −98% | Reverse stock split, May 2024 |
| INNO Holdings (INHD) | Sep 11, 2025 | Aegis, $7.2M | $39.1M | −28.7% | −97% | $50M at-the-market sales agreement, Nov 2025 |
Price returns are split-adjusted, so a reverse split doesn’t count as a gain or a loss. Market caps use the latest cover-page share count, which can lag recent issuance; SUNation’s $20 million raise against a $2.1 million value is an example.
Caveats
The sample covers deals announced in an 8-K or 424B5 that uses the phrase “registered direct offering”. Deals described only as “registered offerings” or “public offerings” aren’t included. Where the pricing release came out after the close but carries that day’s date, our event day is one session early; the method box shows this doesn’t change the picture. Gross proceeds are as stated and sometimes include a concurrent private placement of shares.
The full event list, with every return and classification, is in the CSV download.
How we did it
Sample. We searched SEC EDGAR full-text search for "registered direct offering" in 8-Ks and 424B5 prospectus supplements filed from January 2021 to October 12, 2026: 3,965 filings. We grouped each company's filings within seven days into one offering (2,069 groups) and kept companies whose cover page or press release lists Nasdaq or NYSE American. We dropped 222 groups on other exchanges or with no usable ticker, 173 with no cover-page share count from the last 200 days (mostly foreign issuers that report once a year), 49 with no exchange price history and 153 clearly above our size cutoff. An AI model and a set of text rules each read the remaining 1,472, and we kept new registered direct sales of common stock, ADSs or units. That removed 546 filings that only mentioned an earlier offering, warrant deals or other financings, 19 closing notices whose pricing announcement isn't on EDGAR, 25 preferred-stock or note deals, 12 whose price we couldn't confirm, 33 with a market cap of $300 million or more and 5 duplicates or without a first-day price. That left 832.
Terms. Offering price, shares, pre-funded warrants, gross proceeds, warrants and placement agent come from the pricing press release or 8-K, with the 424B5 cover as a fallback. The AI reading and the text rules agreed on the price for 93% of deals and on whether warrants were attached for 92%; where they differed we used the AI reading and checked samples by hand. Where a combined price for a share and its warrant was given, that's the offering price.
Event day. The first trading session at or after the EDGAR acceptance time of the group's earliest 8-K or 424B5; filings accepted after 4pm Eastern count from the next session. If the attached press release carries an earlier date, we use that date's session. If the 8-K says the agreement was signed on an earlier date, we use the session after signing, since most of these deals are signed after the close and announced before the next open. For 99 offerings the only timing evidence is an 8-K filed after 4pm; leaving them out moves the median discount from −4.6% to −4.4% and the 60-day median from −36% to −37%.
Prices and returns. Alpaca Markets daily bars (SIP feed, split-adjusted). The discount compares the offering price with the unadjusted prior close. Returns run from the prior close; abnormal returns subtract IWM over the same days. Fifteen stocks stopped trading before day +120; we keep them where data exists, and carrying their last close forward changes the +120 median by less than a point. "Closed below the offering price" compares each split-adjusted close in sessions 1 to 20 with the split-adjusted offering price.
The sample excludes Onfolio Holdings (ONFO), which owns Microcap Ledger.
The daily movers email
The biggest micro-cap moves and what's behind them, from the filings. Free, every trading day.
FAQ
- How big is the discount in a registered direct offering?
- Smaller than many people expect. In our 832 microcap deals the median offering priced 4.6% below the prior close, and 31% priced above it. The 10th percentile was a 29% discount. Many deals carry warrants, which add value the headline price doesn't show.
- Why do some registered directs price above the last close?
- Many are 'priced at-the-market under Nasdaq rules', which lets the company skip a shareholder vote if the price is at least Nasdaq's Minimum Price. When warrants come with the shares, the combined price is often set a little above that level. 40% of the deals here used this wording; their median discount was 0.6%.
- Does the stock usually fall below the offering price?
- In this sample, yes. 86% closed below the offering price at least once in the first 20 sessions, and about half did on the first day. That pattern held whether or not the deal had warrants, though it was more common with them (94% vs 73%).
Sources
- SEC EDGAR full-text search ("registered direct offering", 8-K and 424B5, 2021 to 2026)
- SEC EDGAR submissions and XBRL APIs (filing times, share counts)
- Alpaca Markets historical stock bars (SIP, split-adjusted)
- Nasdaq Listing Rule 5635(d), definition of Minimum Price
- GeoVax Labs 8-K, BARDA award for a Phase 2b COVID-19 vaccine trial · 8-K · filed 2024-06-18
- Veritone 8-K, underwritten offering at $2.63 · 8-K · filed 2025-09-12
- Palladyne AI 8-K, at-the-market sales agreement · 8-K · filed 2024-12-31
- Bellerophon Therapeutics 8-K, Phase 3 REBUILD study update · 8-K · filed 2023-05-11
- INNO Holdings 8-K, standby equity purchase agreement · 8-K · filed 2025-07-08
- SUNation Energy 8-K, increase in authorized shares · 8-K · filed 2025-04-04
- Aclarion 8-K, underwritten unit offering · 8-K · filed 2025-01-30
- Aditxt 8-K, reverse stock split · 8-K · filed 2024-10-03
- Greenwave Technology Solutions 8-K, reverse stock split · 8-K · filed 2024-06-03
- INNO Holdings 8-K, $50 million at-the-market sales agreement · 8-K · filed 2025-11-13